ATE201990T1 - Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren - Google Patents

Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren

Info

Publication number
ATE201990T1
ATE201990T1 AT94909927T AT94909927T ATE201990T1 AT E201990 T1 ATE201990 T1 AT E201990T1 AT 94909927 T AT94909927 T AT 94909927T AT 94909927 T AT94909927 T AT 94909927T AT E201990 T1 ATE201990 T1 AT E201990T1
Authority
AT
Austria
Prior art keywords
inclusion complexes
pct
date
ranitidine
hxdrochloride
Prior art date
Application number
AT94909927T
Other languages
English (en)
Inventor
Wilfried Fischer
Karin Klokkers
Original Assignee
Hexal Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal Ag filed Critical Hexal Ag
Application granted granted Critical
Publication of ATE201990T1 publication Critical patent/ATE201990T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT94909927T 1993-03-05 1994-03-04 Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren ATE201990T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9306024 1993-03-05
PCT/EP1994/000645 WO1994020091A1 (en) 1993-03-05 1994-03-04 Crystalline cyclodextrin inclusion complexes of ranitidine hydrochloride and process for their preparation

Publications (1)

Publication Number Publication Date
ATE201990T1 true ATE201990T1 (de) 2001-06-15

Family

ID=10984320

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94909927T ATE201990T1 (de) 1993-03-05 1994-03-04 Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren

Country Status (10)

Country Link
US (1) US5665767A (de)
EP (1) EP0687174B1 (de)
JP (1) JPH09502698A (de)
AT (1) ATE201990T1 (de)
CA (1) CA2157190A1 (de)
CZ (1) CZ224995A3 (de)
DE (1) DE69427467T2 (de)
RU (1) RU2143896C1 (de)
WO (1) WO1994020091A1 (de)
ZA (1) ZA941544B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA955582B (en) * 1994-07-06 1996-02-26 Group Services Proprietary Lim Inclusion complexes of ranitidine
HU229833B1 (en) * 1996-11-18 2014-09-29 Biotechnolog Forschung Gmbh Epothilone d production process, and its use as cytostatic as well as phytosanitary agents
AU1513699A (en) * 1998-08-18 2000-03-14 Nikolai Borisovich Leonidov Physically stable and x-ray amorphous form of hydrochloride ranitidine having anincreased antitumoral activity and method for producing the same
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
ITMI20012749A1 (it) * 2001-12-21 2003-06-21 Chiesi Farma Spa Procedimento per la preparazione mediante trattamento con microonde di composti di inclusione tra farmaco e ciclodestrine e prodotti ottenut
US20040202694A1 (en) * 2003-04-11 2004-10-14 Vascular Control Systems, Inc. Embolic occlusion of uterine arteries
JP2008508332A (ja) * 2004-08-02 2008-03-21 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ ピロキシカム:ベータシクロデキストリン包接化合物の製造方法
EP2439201B1 (de) 2006-06-16 2013-08-07 H. Lundbeck A/S Verbindungen mit kombinierter sert, 5-ht3 und 5-ht1a-aktivität
US8889243B2 (en) 2012-08-16 2014-11-18 3M Innovative Properties Company Mechanical fastening nets and methods of making the same
WO2021079183A1 (en) * 2019-10-21 2021-04-29 Sms Pharmaceuticals Limited Isopropyl alcohol solvent free crystalline ranitidine hydrochloride form-2 which is free of nitrosamine (ndma) impurity
EP4121116A4 (de) * 2020-03-19 2024-06-12 University of Pittsburgh - of the Commonwealth System of Higher Education Stabilisierung von verbindungen als cyclodextrinkomplexe

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
EP0518930A4 (en) * 1990-03-02 1993-09-15 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
IT1241417B (it) * 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione

Also Published As

Publication number Publication date
DE69427467T2 (de) 2002-06-06
CZ224995A3 (en) 1995-12-13
JPH09502698A (ja) 1997-03-18
US5665767A (en) 1997-09-09
ZA941544B (en) 1994-10-31
CA2157190A1 (en) 1994-09-15
RU2143896C1 (ru) 2000-01-10
EP0687174A1 (de) 1995-12-20
EP0687174B1 (de) 2001-06-13
DE69427467D1 (de) 2001-07-19
WO1994020091A1 (en) 1994-09-15

Similar Documents

Publication Publication Date Title
ATE201990T1 (de) Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren
NO954320D0 (no) Lyosfærer omfattende gonadotropin
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
ATE319480T1 (de) Acylierte zyklodextrin guest-inklusion komplexe
DK1140993T3 (da) Glycopeptidderivater og farmaceutiske præparater indeholdende dem
BR9608041B8 (pt) Oligossacarídeo sulfatado, e, composição farmacêutica ou veterinária para tratamento anti-angiogênico, anti-metastático e/ou anti-inflamatório.
DE69428334D1 (de) Wässrige Lösungen enthaltend Inklusionskomplexe aus Benzothiophenderivaten und Cyclodextrinen
DK1200418T3 (da) Nematodicide trifluorbutener
BR9808396A (pt) Processo para aumentar a deposição de um agente benéfico de uma composição em barra, e, barra
DE60112330D1 (en) Pyrazolopyridinderivate
MEP9309A (en) Novel oligosaccharides, preparation method and pharmaceutical compositions containing the same
DE60013161D1 (de) Neue fucosylierte oligosaccharide und verfahren zu deren herstellung
DE69412760T2 (de) Neue inklusionskomplexe von salzen von nimesulide mit cyclodextrinen
DE69906345D1 (de) Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten
DE50112128D1 (de) Retardpartikeldispersion
DK0422497T3 (da) Inklusionskomplekser med Silybinin, deres fremstilling af farmaceutiske præparater, der indeholder dem
DE69933885D1 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen
IT1304183B1 (it) Complessi di proantocianidina a2 con fosfolipidi come agentiantiaterosclerotici.
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
FR2811572B1 (fr) Utilisation de cyclodextrines polysulfatees pour le traitement de l'arthrose
ATE254460T1 (de) Anhydrovinblastin zur behandlung von krebs
EE200200302A (et) Küllastumata 14,15-tsüklopropanoandrostaanid, nende valmistamise meetod ja neid ühendeid sisaldavadfarmatseutilised kompositsioonid
TWI231815B (en) Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties